Results 51 to 60 of about 3,216,105 (293)
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis [PDF]
The Korean Journal of Internal MedicineBackground/Aims The aim of this study was to compare the short- and long-term retention rates of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in Korean patients with seropositive rheumatoid arthritis.
Bong-Woo Lee +2 more
doaj +1 more source
Vaccines, 2022 Background: Seroconversion and longevity of vaccine-induced immune response is blunted in immune-mediated inflammatory disease (IMID) patients owing to immunosuppressive regimens.
Ainsley Ryan Yan Bin Lee +2 more
doaj +1 more source
DRUG SAFETY DATA COVERAGE IN MEDICAL LITERATURE
Научно-практическая ревматология, 2015 The paper discusses whether it is expedient to use the standards approved by the editorial staff of a number of medical journals for original articles on the therapeutic effect of drugs, including antirheumatic agents since this is of importance for the ...
Yu. V. Muravyev, L. A. Muravyeva
doaj +1 more source
Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases [PDF]
, 2010 The treatment of rheumatic diseases has been the focus of many clinical studies aiming to achieve the best combination of drugs for symptom reduction.
Martins, Albino +4 more
core +1 more source
Metabolic Consequences of Rheumatoid Arthritis
Arthritis Care &Research, EarlyView.Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry +2 more
wiley +1 more source
Eosinophilic fasciitis after parasite infection
Rheumatology, 2016 Eosinophilic fasciitis is a systemic inflammatory disease characterized by symmetrical swelling and skin induration of the distal portions of the arms and/or legs, evolving into a scleroderma-like appearance, accompanied by peripheral blood eosinophilia.
Marta Oliveira +2 more
doaj +1 more source
Journal of Current Research in Scientific Medicine, 2022 Background: Prescription analysis is the simplest method to observe the current treatment practice in any health-care setting. Biopharmaceuticals are a class of drugs that hold great promise in treating diseases.
Vikas Yadav +2 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective Gastrointestinal perforation (GIP) is a rare and life‐threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta‐analysis approach.
Thipsukhon Sathapanasiri +7 more
wiley +1 more source
Frontiers in Pharmacology, 2020 Mesenchymal stem cell (MSC)–based articular regeneration might be beneficial for both protecting and rebuilding cartilaginous tissues in the management of rheumatoid arthritis. However, it is unclear how current immunosuppressive strategies influence the
Shuang Liu +3 more
doaj +1 more source